Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry criticises “politicisation” of drug reimbursement decisions in Australia

This article was originally published in SRA

Executive Summary

Pharmaceutical companies are warning the Australian government about the potential consequences of a recent policy change that they believe is resulting in the government delaying indefinitely the final decision on whether drugs should be reimbursed under the country's state-funded pharmaceutical benefits scheme. Jamie Nicholson, spokesperson for the industry association Medicines Australia, said that he was "aware of at least a couple of companies who have hit the pause button in terms of bringing new medicines to Australia until the policy outlook becomes clearer"1.

Advertisement
Advertisement
UsernamePublicRestriction

Register

PS116158

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel